AAAAAA
Results:
1-11
|
Results: 11
Authors:
Petersdorf, SH
Kopecky, KJ
Head, DR
Boldt, DH
Balcerzak, SP
Wun, T
Roy, V
Veith, RW
Appelbaum, FR
Citation: Sh. Petersdorf et al., Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblasticleukemia: a Southwest Oncology Group Study, LEUKEMIA, 15(2), 2001, pp. 208-216
Authors:
Gaynor, ER
Unger, JM
Miller, TP
Grogan, TM
White, LA
Mills, GM
Balcerzak, SP
Varterasian, M
LeBlanc, M
Fisher, RI
Citation: Er. Gaynor et al., Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study, J CL ONCOL, 19(3), 2001, pp. 750-755
Authors:
Hussain, MHA
Glass, TR
Forman, J
Sakr, W
Smith, DC
Al-Sarraf, M
Jones, J
Balcerzak, SP
Crawford, ED
Grossman, HB
Citation: Mha. Hussain et al., Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group study, J UROL, 165(1), 2001, pp. 56-60
Authors:
Kraut, EH
Balcerzak, SP
Young, D
O'Rourke, MA
Petrus, JJ
Kuebler, JP
Mayernik, DG
Citation: Eh. Kraut et al., A phase II study of 9-aminocamptothecin in patients with refractory breastcancer, CANCER INV, 18(1), 2000, pp. 28-31
Authors:
Fisher, RI
Dana, BW
LeBlanc, M
Kjeldsberg, C
Forman, JD
Unger, JM
Balcerzak, SP
Gaynor, ER
Roy, V
Miller, T
Citation: Ri. Fisher et al., Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809, J CL ONCOL, 18(10), 2000, pp. 2010-2016
Authors:
Williamson, SK
Lew, D
Miller, GJ
Balcerzak, SP
Baker, LH
Crawford, ED
Citation: Sk. Williamson et al., Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma - A Southwest Oncology Group study, CANCER, 88(5), 2000, pp. 1159-1165
Authors:
Kish, JA
Benedetti, JK
Balcerzak, SP
Veith, RW
Davis, R
Pollock, TW
Schuller, DE
Ensley, SE
Citation: Ja. Kish et al., Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neckcancer: A Southwest Oncology Group study, CA J SCI AM, 5(5), 1999, pp. 307-311
Authors:
Hesketh, PJ
Crowley, JJ
Burris, HA
Williamson, SK
Balcerzak, SP
Peereboom, D
Goodwin, JW
Gross, HM
Moore, DF
Livingston, RB
Gandara, DR
Citation: Pj. Hesketh et al., Evaluation of docetaxel in previously untreated extensive-stage small celllung cancer: A Southwest Oncology Group phase II trial, CA J SCI AM, 5(4), 1999, pp. 237-241
Authors:
Sondak, VK
Liu, PY
Flaherty, LE
Fletcher, WS
Periman, P
Gandara, DR
Taylor, SA
Balcerzak, SP
Meyskens, FL
Citation: Vk. Sondak et al., A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group Study, CA J SCI AM, 5(1), 1999, pp. 41-47
Authors:
Grunberg, SM
Crowley, J
Hande, KR
Giroux, D
Munshi, N
Lan, DHM
Schroder, LE
Zangmeister, MH
Balcerzak, SP
Hynes, HE
Gandara, DR
Citation: Sm. Grunberg et al., Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study, CANC CHEMOT, 44(6), 1999, pp. 461-468
Authors:
Meyers, FJ
Lew, D
Lara, PN
Williamson, S
Marshall, E
Balcerzak, SP
Rivkin, SE
Samlowski, W
Crawford, ED
Citation: Fj. Meyers et al., Phase II trial of edatrexate in relapsed or refractory germ cell tumors: ASouthwest Oncology Group study (SWOG 9124), INV NEW DR, 16(4), 1998, pp. 347-351
Risultati:
1-11
|